Skip to content
lifestyle.emphas.is
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Palvella Therapeutics Inc.
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
October 15, 2026
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
October 12, 2026
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
September 28, 2026
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
September 9, 2026
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 2, 2026
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
August 31, 2026
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
1
2
3
Next Page
→